Gujarat Fluorochemicals Q4FY26 Results: Revenue Up, Profit Falls

Gujarat Fluorochemicals reported a mixed set of earnings for the March quarter of FY26. The financials showed healthy revenue growth. However, profitability remained under pressure due to multiple factors.

For Q4FY26, the company posted consolidated revenue from operations of ₹1,369 crore, up 11.8% year-on-year from ₹1,225 crore in Q4FY25 and up 20.5% sequentially from ₹1,136 crore in Q3FY26. Total income for the quarter stood at ₹1,375 crore, compared with ₹1,251 crore a year earlier.

Gujarat Fluorochemicals shares fell after the results announcement. On 27 May 2026, company shares were closed at ₹3,682.10, down by 2.70%.

Profit Under Pressure Despite Revenue Growth

Profit performance remained weak. Net profit (PAT) came in at ₹112 crore, which is a 41% YoY decline from ₹191 crore reported in the same quarter last year. On a quarter-on-quarter basis, PAT was marginally higher when compared to ₹103 crore in Q3FY26.

Operationally, Earnings Before Interest, Taxes, Depreciation and Amortisation (EBITDA) came in at around ₹308 crore. EBITDA margin narrowed to nearly 23% from around 25% in the year-ago period. The given figures indicate cost pressure and continued losses in the battery materials segment. The EV products business reported an EBITDA loss during the quarter, which weighed on consolidated margins.

FY26 Performance and Dividend Announcement

For the full financial year FY26, Gujarat Fluorochemicals reported revenue from operations of ₹4,996 crore, up 5.5% when compared to ₹4,737 crore in FY25. Total income stood at ₹5,038 crore, versus ₹4,795 crore in the previous year. Full-year net profit rose 5.1% to ₹574 crore, compared with ₹546 crore in FY25. Earnings per share for FY26 came in at ₹52.26, against ₹49.69 a year earlier.

Segment-wise, the core chemicals business remained the key growth driver. In FY26, chemicals revenue rose to ₹5,030 crore and segment EBITDA improved to ₹1,371 crore. The EV products segment did bring in more revenue, but it continued to stay in the red at the EBITDA level.

Also Read - Manipal Health Begins Investor Meetings For USD 1.1 Billion IPO Amid Slow Market

The board has recommended a final dividend of ₹3 per equity share (300% on the face value of ₹1) for FY26, subject to shareholder approval at the upcoming annual general meeting.

Sources:

Business Standard

CNBC TV18

Free Press Journal